
Mounjaro
Tirzepatide
- SKU
- 0002-4052
- UPC
- 0300023002013
- Mfr
- Eli Lilly and Company
2.4 ml in 1 vial, multi-dose, 1 vial, multi-dose in 1 carton
$1,454.99
Price for one pack
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
- Strength
- Tirzepatide 4.17 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
Pharmacologic class
- G-Protein-linked Receptor InteractionsMechanism
- GLP-1 Receptor AgonistEstablished class
- Glucagon-like Peptide-1 (GLP-1) AgonistsMechanism
- Glucose-dependent Insulinotropic Polypeptide Receptor AgonistEstablished class
- Brand name
- Mounjaro
- Generic name
- Tirzepatide
- Manufacturer
- Eli Lilly and Company
- Product NDC (SKU)
- 0002-4052
- UPC
- 0300023002013, 0300021152017, 0300022423017, 0300024612112, 0300024052116, 0300024304116, 0300021243012, 0300024523111
- Active ingredients
- Tirzepatide 4.17 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA215866
- Marketed since
- January 7, 2026
- Label revised
- August 27, 2026
| Package NDC | Description |
|---|---|
| 0002-4052-11 | 1 VIAL, MULTI-DOSE in 1 CARTON (0002-4052-11) / 2.4 mL in 1 VIAL, MULTI-DOSE |
Reading this NDC
0002-4052-11
- 01Labeler code
- Eli Lilly and Company
- 02Product code
- Mounjaro, injection, solution
- 03Package code
- 1 vial, multi-dose in 1 carton (0002-4052-11) / 2.4 ml in 1 vial, multi-dose
Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.
Warning: Risk of thyroid c-cell tumors
In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions
and Nonclinical Toxicology]. MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO [see Contraindications
and Warnings and Precautions]. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Read before you order

Weight management · 3 min read
How GLP-1 weight-loss medicines work
Semaglutide, tirzepatide and liraglutide explained: how they reduce appetite, how quickly they work and what to expect in the first months.

Weight management · 2 min read
Managing nausea and other GLP-1 side effects
Practical ways to cope with nausea, constipation and reflux on semaglutide or tirzepatide, and the warning signs that need a doctor.

Weight management · 2 min read
Orlistat, phentermine and Contrave: the older weight-loss medicines
How orlistat, phentermine and naltrexone-bupropion work, who they suit and the side effects to know about before starting.
More in Weight Management
View all
Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 0135-0461
- Mfr
- Haleon US Holdings LLC
From $47.99Min. 7 packs

Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 71610-805
- Mfr
- Aphena Pharma Solutions - Tennessee, LLC
From $1,329.43

Brand · Tablet
Contrave Extended-Release
Naltrexone Hydrochloride 8 mg/1, Bupropion Hydrochloride 90 mg/1
- SKU
- 51267-890
- Mfr
- Nalpropion Pharmaceuticals LLC
From $199.00Min. 2 packs

Brand · Injection
Mounjaro Kwikpen
Tirzepatide 20.8 mg/mL
- SKU
- 0002-3422
- Mfr
- Eli Lilly and Company
From $1,454.99